Press release content from Globe Newswire. The AP news staff was not involved in its creation.
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
Erytech Pharma S.A.April 20, 2021 GMT
ERYTECH Requested a Pre-BLA Meeting with the FDA to Discuss Path to Approval in ALL
ERYTECH invited by FDA to request a pre-BLA meeting
First step in the marketing approval process with the FDA for eryaspase for the treatment of hypersensitive ALL patients based on the positive results of the NOPHO-sponsored Phase 2 clinical trial
Lyon (France) and Cambridge, MA (U.S.), April 20, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the initiation of the process of seeking marketing approval from the U.S. Food and Drug Administration (US FDA) for its lead product candidate eryaspase in patients with acute ly
Press release content from PR Newswire. The AP news staff was not involved in its creation.
OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4
April 6, 2021 GMT
TAIPEI, Taiwan, April 6, 2021 /PRNewswire/ OBI Pharma, Inc. (TPEx: 4174) today announced the data highlighting the characteristics and antitumor efficacy of OBI-3424 and animal studies of OBI-998, as well as the T-cell inhibitory roles of Globo-H and SSEA-4 in the tumor microenvironment, will be presented at the American Association of Cancer Research (AACR) Virtual Annual Meeting from April 10–15, 2021.
OBI’s Chief Scientific Officer, Ming-Tain Lai, Ph. D stated that “OBI Pharma is proud to present at the AACR Annual Meeting our latest findings on our Cancer portfolio products, OBI-3424 and OBI-998. OBI-3424′s impressive anti-AKR1C3 tumor activities in various cancer models, and enhanced efficacy when used in combination with standard-of-care chemothe
Changing diet and exercise can make chemotherapy more effective in youth with leukemia
Overweight children and adolescents receiving chemotherapy for treatment of leukemia are less successful battling the disease compared to their lean peers. Now, research conducted at the Cancer and Blood Disease Institute at Children s Hospital Los Angeles indicates that modest changes in diet and exercise can greatly increase survival in youth treated for acute lymphoblastic leukemia (ALL), the most common childhood cancer.
To our knowledge, this is the first study to show that by limiting calories and increasing exercise we can make chemotherapy more effective in eliminating leukemia cells within the first month of therapy, decreasing the chances of disease relapse in children and adolescents.
E-Mail
Los Angeles (April 1, 2021) Overweight children and adolescents receiving chemotherapy for treatment of leukemia are less successful battling the disease compared to their lean peers. Now, research conducted at the Cancer and Blood Disease Institute at Children s Hospital Los Angeles indicates that modest changes in diet and exercise can greatly increase survival in youth treated for acute lymphoblastic leukemia (ALL), the most common childhood cancer. To our knowledge, this is the first study to show that by limiting calories and increasing exercise we can make chemotherapy more effective in eliminating leukemia cells within the first month of therapy, decreasing the chances of disease relapse in children and adolescents, says Principal Investigator Etan Orgel, MD, MS, Director of the Medical Supportive Care Service in the Cancer and Blood Disease Institute at Children s Hospital Los Angeles. The study is published in the American Society of Hematology s journal
/PRNewswire/ New research published today in the journal Blood Advances is the first to show that restricting calories, reducing fat and sugar intake, and.